实用药物与临床
實用藥物與臨床
실용약물여림상
PRACTICAL PHARMACY AND CLINICAL REMEDIES
2015年
4期
390-393
,共4页
雷公藤内酯醇%糖尿病肾病%大鼠%Glut-1%Glut-4
雷公籐內酯醇%糖尿病腎病%大鼠%Glut-1%Glut-4
뢰공등내지순%당뇨병신병%대서%Glut-1%Glut-4
Triptolide%Diabetic nephropathy%Rats%Glut-1%Glut-4
目的：探讨雷公藤内酯醇对糖尿病肾病大鼠肾内Glut-1、Glut-4表达的影响。方法将45只大鼠按体重随机分为正常对照组( C 组,13只)和糖尿病模型组(32只)。模型组腹腔注射链脲菌素( STZ )52 mg/kg,1次/d,连续5 d；正常对照组仅腹腔注射等体积上述缓冲液。完成STZ 注射72 h后,尾静脉采血测空腹血糖,并同时测尿糖,血糖≥16．7 mmol/L、尿糖+++以上者列入糖尿病观察对象。将造模成功的28只雄性大鼠,按体重、空腹血糖随机分为DM模型组对照( DM组,14只)、雷公藤内酯醇组( TP组,14只)。结果 DM组、TP组第4、第8周的24 h尿mALB定量较C组明显增加(P<0．01),且DM组第8周高于第4周(P<0．01),TP组第8周较第4周明显降低( P<0．01)。 DM组系膜细胞及上皮细胞Glut-1的表达较正常对照组均明显增加(P<0．05),Glut-4的表达均有所减少(P<0．05)。与DM组比较,TP组系膜细胞及上皮细胞Glut-1的表达降低(P<0．01)；Glut-4在系膜细胞的表达升高(P<0．05),在上皮细胞的表达变化不明显(P>0．05)。结论雷公藤内酯醇能明显降低糖尿病肾病大鼠肾小球系膜细胞及上皮细胞内的Glut-1含量,增高Glut-4在肾小球系膜细胞的表达。
目的：探討雷公籐內酯醇對糖尿病腎病大鼠腎內Glut-1、Glut-4錶達的影響。方法將45隻大鼠按體重隨機分為正常對照組( C 組,13隻)和糖尿病模型組(32隻)。模型組腹腔註射鏈脲菌素( STZ )52 mg/kg,1次/d,連續5 d；正常對照組僅腹腔註射等體積上述緩遲液。完成STZ 註射72 h後,尾靜脈採血測空腹血糖,併同時測尿糖,血糖≥16．7 mmol/L、尿糖+++以上者列入糖尿病觀察對象。將造模成功的28隻雄性大鼠,按體重、空腹血糖隨機分為DM模型組對照( DM組,14隻)、雷公籐內酯醇組( TP組,14隻)。結果 DM組、TP組第4、第8週的24 h尿mALB定量較C組明顯增加(P<0．01),且DM組第8週高于第4週(P<0．01),TP組第8週較第4週明顯降低( P<0．01)。 DM組繫膜細胞及上皮細胞Glut-1的錶達較正常對照組均明顯增加(P<0．05),Glut-4的錶達均有所減少(P<0．05)。與DM組比較,TP組繫膜細胞及上皮細胞Glut-1的錶達降低(P<0．01)；Glut-4在繫膜細胞的錶達升高(P<0．05),在上皮細胞的錶達變化不明顯(P>0．05)。結論雷公籐內酯醇能明顯降低糖尿病腎病大鼠腎小毬繫膜細胞及上皮細胞內的Glut-1含量,增高Glut-4在腎小毬繫膜細胞的錶達。
목적：탐토뢰공등내지순대당뇨병신병대서신내Glut-1、Glut-4표체적영향。방법장45지대서안체중수궤분위정상대조조( C 조,13지)화당뇨병모형조(32지)。모형조복강주사련뇨균소( STZ )52 mg/kg,1차/d,련속5 d；정상대조조부복강주사등체적상술완충액。완성STZ 주사72 h후,미정맥채혈측공복혈당,병동시측뇨당,혈당≥16．7 mmol/L、뇨당+++이상자렬입당뇨병관찰대상。장조모성공적28지웅성대서,안체중、공복혈당수궤분위DM모형조대조( DM조,14지)、뢰공등내지순조( TP조,14지)。결과 DM조、TP조제4、제8주적24 h뇨mALB정량교C조명현증가(P<0．01),차DM조제8주고우제4주(P<0．01),TP조제8주교제4주명현강저( P<0．01)。 DM조계막세포급상피세포Glut-1적표체교정상대조조균명현증가(P<0．05),Glut-4적표체균유소감소(P<0．05)。여DM조비교,TP조계막세포급상피세포Glut-1적표체강저(P<0．01)；Glut-4재계막세포적표체승고(P<0．05),재상피세포적표체변화불명현(P>0．05)。결론뢰공등내지순능명현강저당뇨병신병대서신소구계막세포급상피세포내적Glut-1함량,증고Glut-4재신소구계막세포적표체。
Objective To discuss the influence of triptolide on the expression of Glut-1,Glut-4 in kidney of diabetic nephropathy rats. Methods 45 rats were randomly divided into two groups according to weight: normal con-trol group (group C,n=13) and diabetic model group (n=32). Rats in model group were intraperitoneally injected streptozotocin ( STZ) 52 mg/kg for 5 d continuously;rats in group C were given intraperitoneal injection of equal vol-ume of the buffer solution. At 72 h after the injection,the levels of fasting blood glucose and urine glucose were detec-ted,and the rats with blood glucose≥16. 7 mmol/L,urine glucose more than +++were included as the diabetes ob-jects. The 28 male rats (successful model) were randomly divided into DM model group (DM group,n=14) and trip-tolide group (TP group,n=14). Results At the 4th and 8th weeks,the 24 h urinary mALB level in DM group and TP group significantly increased than that of group C (P<0. 01),the mALB in DM group at the 8th week was higher than that at the 4th week (P<0. 01),but the mALB in TP group at the 8th week reduced (P<0. 01). The expression of Glut-1 in mesangial and epithelial cells in DM group increased more significantly than that of group C (P<0. 05), and the expression of Glut-4 reduced (P<0. 05). Compared with DM group,the expression of Glut-1 in mesangial and epithelial cells of group PT was significantly lower (P<0. 01),the expression of Glut-4 in mesangial cells increased (P<0. 05),no significant difference was found in the expression of epithelial cell (P>0. 05). Conclusion Triptolide can significantly reduce the content of Glut-1 in glomerular mesangial and epithelial cells of diabetic nephropathy rats, increase the Glut-4 expression in glomerular mesangial cells.
